RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
  • Your browser version may not work well with NCBI's Web applications. More information here...

Results: 1 to 20 of 101

1.

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group.

Diabetes Care. 2009 Jan;32(1):84-90. Epub 2008 Oct 17.PMID: 18931095 [PubMed - in process]Related articlesFree article

2.

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L; LEAD-4 Study Investigators.

Diabetes Care. 2009 Jul;32(7):1224-30. Epub 2009 Mar 16.PMID: 19289857 [PubMed - indexed for MEDLINE]Related articlesFree article

3.

Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

Nauck M, Marre M.

Postgrad Med. 2009 May;121(3):5-15.PMID: 19491535 [PubMed - indexed for MEDLINE]Related articlesFree article

4.

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R.

Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

5.

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group.

Diabetes Care. 2004 Jun;27(6):1335-42.PMID: 15161785 [PubMed - indexed for MEDLINE]Related articlesFree article

6.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group.

Diabet Med. 2009 Mar;26(3):268-78.PMID: 19317822 [PubMed - indexed for MEDLINE]Related articles

7.

Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study.

Gottschalk M, Danne T, Vlajnic A, Cara JF.

Diabetes Care. 2007 Apr;30(4):790-4.PMID: 17392540 [PubMed - indexed for MEDLINE]Related articlesFree article

8.

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.

Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group.

Diabet Med. 2005 Aug;22(8):1016-23.PMID: 16026367 [PubMed - indexed for MEDLINE]Related articles

9.

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.

Umpierrez G, Issa M, Vlajnic A.

Curr Med Res Opin. 2006 Apr;22(4):751-9.PMID: 16684436 [PubMed - indexed for MEDLINE]Related articles

10.

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group.

Diabetologia. 2009 Oct;52(10):2046-55. Epub 2009 Aug 14.PMID: 19688338 [PubMed - in process]Related articlesFree article

11.

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.

Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J; NN2211-1499 Study Group.

Exp Clin Endocrinol Diabetes. 2006 Sep;114(8):417-23.PMID: 17039422 [PubMed - indexed for MEDLINE]Related articles

12.

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group.

Lancet. 2009 Feb 7;373(9662):473-81. Epub 2008 Sep 24.PMID: 18819705 [PubMed - indexed for MEDLINE]Related articles

13.

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

14.

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.

Seino Y, Rasmussen MF, Zdravkovic M, Kaku K.

Diabetes Res Clin Pract. 2008 Aug;81(2):161-8. Epub 2008 May 20.PMID: 18495285 [PubMed - indexed for MEDLINE]Related articles

15.

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

Harder H, Nielsen L, Tu DT, Astrup A.

Diabetes Care. 2004 Aug;27(8):1915-21.PMID: 15277417 [PubMed - indexed for MEDLINE]Related articlesFree article

16.

Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes.

Kabadi UM, Kabadi M.

Diabetes Res Clin Pract. 2006 Jun;72(3):265-70. Epub 2006 Jan 10.PMID: 16406190 [PubMed - indexed for MEDLINE]Related articles

17.

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group.

Diabetes Care. 2007 Aug;30(8):1979-87. Epub 2007 May 7. Erratum in: Diabetes Care. 2008 Aug;31(8):1713. PMID: 17485570 [PubMed - indexed for MEDLINE]Related articlesFree article

18.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

19.

Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

Luis Bautista J, Bugos C, Dirnberger G, Atherton T.

Clin Ther. 2003 Jan;25(1):194-209.PMID: 12637120 [PubMed - indexed for MEDLINE]Related articles

20.

Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.

Neumiller JJ, Campbell RK.

Ann Pharmacother. 2009 Sep;43(9):1433-44. Epub 2009 Jul 28. Review.PMID: 19638470 [PubMed - indexed for MEDLINE]Related articles

Supplemental Content

Filter your results:

Find related data

Recent activity